| Literature DB >> 35120539 |
Tessa Parkes1,2, Catriona Matheson3,4, Hannah Carver3,4, Rebecca Foster3, John Budd5, Dave Liddell6, Jason Wallace6, Bernie Pauly7, Maria Fotopoulou3,4, Adam Burley8, Isobel Anderson4, Tracey Price3, Joe Schofield3, Graeme MacLennan9.
Abstract
BACKGROUND: For people experiencing homelessness and problem substance use, access to appropriate services can be challenging. There is evidence that the development of trusting relationships with non-judgemental staff can facilitate service engagement. Peer-delivered approaches show particular promise, but the evidence base is still developing.Entities:
Keywords: Alcohol; Drugs; Feasibility; Harm reduction; Homelessness; Intervention; Mixed methods; Peer support; Substance use
Mesh:
Year: 2022 PMID: 35120539 PMCID: PMC8815224 DOI: 10.1186/s12954-021-00582-5
Source DB: PubMed Journal: Harm Reduct J ISSN: 1477-7517
Practical and emotional support provided by Peer Navigators
| Support to access healthcare services, including attending appointments to GPs, physiotherapists, dieticians, and dentists |
| Access to substance use treatment |
| Money for travel to/from appointments |
| Advocacy at appointments on participants’ behalf |
| Access to housing |
| Money to purchase household appliances |
| Access to benefits, including phone calls and attending appointments |
| Paying for food and hot drinks |
| Clothing, stamps, phone calls |
| Accompanying to hairdressers |
| Helping to secure volunteering and employment opportunities |
| Helping to connect/reconnect with family, friends and children |
| Listening |
| Being reliable and consistent |
Measures
| Tool | Purpose | Scoring |
|---|---|---|
| Socio-demographic, health and housing circumstance questionnaire | To understand participants’ socio-demographic characteristics, housing status/quality, general health status, education, medication use, and future service use | Questionnaire consisted of questions regarding demographics, with yes/no options, ranges and free text. No scores were generated |
| Patient Health Questionnaire 9 (PHQ-9) [ | To identify symptoms of depression (measure combined with GAD-7) | PHQ-9 is a 9-item scale. Scoring can range from 0 to 27, with scores of > 10 indicating moderate depression and > 15 moderately-severe depression and > 20 severe depression |
| Generalised Anxiety Disorder (GAD-7) [ | To identify symptoms of anxiety (measure combined with PHQ-9) | GAD-7 is a 7-item scale. Scoring can range from 0 to 21, with scores of > 10 indicating moderate anxiety and > 15 severe anxiety |
| Maudsley Addiction Profile (MAP) [ | To identify type, levels, and risk factors relating to drug and alcohol use. Slight changes were made to make it more suitable for the study population, including adding a question on overdose and asking about use of other drugs not included (such as Novel Psychoactive Substances). Physical health domain also used | MAP is a 60 item (with 8 additional items added to section A for the SHARPS study) Scale in four domains. Each domain is scored depending on the structure, with some using free text and others Likert scales. No overall score is generated but mean/median scores across the domains were used |
| Substance Use Recovery Evaluator (SURE) [ | To identify drinking and drug use, self-care, relationships, material resources, outlook on life, and importance of these factors | SURE is a 21-item scale split into three sections, only two of which are scored. Scores range from 21 to 63, with higher scores indicating greater levels of recovery capital |
| RAND Short Form-36 (SF-36) [ | To identify physical and emotional health status, the effect of health on daily activities and social activities, and experiences of pain | SF-36 is a 36-item scale. Scoring ranges from 0 to 100 on each of the eight domains, with lower scores indicating poorer health |
| Consultation and Relational Empathy (CARE) [ | To assess the levels of empathy within the relationship between participant and their Peer Navigator | CARE is a 10-item scale. Scoring ranges from 10 to 50, with higher scores indicating greater levels of empathy within the relationship |
Fig. 1CONSORT flow diagram
Pre-intervention demographics for whole cohort and participants that completed both baseline and follow-up measurements
| Variable | Whole cohort | Baseline for both measures cohort | ||
|---|---|---|---|---|
| Age years—mean (SD) | 38.6 (8.7) | 38.2 (8.0) | ||
Self-reported substance use at baseline and follow-up
| Substance | Baseline whole cohort | Baseline for both measures cohort | Follow-up |
|---|---|---|---|
| 21 (48) | 16 (53) | 15 (50) | |
| Days | 12 [2, 30] | 19 [2, 30] | 5 [1, 30] |
| 22 (50) | 15 (50) | 9 (30) | |
| Inject | 9 | 5 | 6 |
| Smoke | 13 | 10 | 3 |
| Days | 13 [2, 30] | 6 [1, 30] | 2 [1, 3] |
| 23 (52) | 15 (50) | 11 (37) | |
| Inject | 17 | 12 | 8 |
| Smoke | 5 | 2 | 2 |
| Days | 13 [2, 30] | 11 [1, 21] | 2 [1, 8] |
| 25 (57) | 17 (57) | 23 (77) | |
| Oral | 22 | 14 | 22 |
| Sniff | 1 | ||
| Days | 30 [30, 30] | 30 [30, 30] | 30 [30, 30] |
| 13 (30) | 9 (30) | 7 (23) | |
| Days | 30 [4, 30] | 30 [4, 30] | 30 [4, 30] |
| 15 (34) | 11 (37) | 7 (23) | |
| Oral | 14 | 9 | 6 |
| Snort/sniff | 1 | 1 | 1 |
| Days | 3 [2, 30] | 10 [2, 30] | 2 [2, 30] |
| 19 (43) | 13 (43) | 13 (43) | |
| Smoke | 19 | 13 | 13 |
| Days | 15 [2, 27] | 15 [14, 30] | 30 [30, 30] |
Cells are n and (%) except for rows with days which summarises median [25th, 75th centile] days of use. *One participant who completed the baseline measures did not complete the full suite of measures (2/6 completed), hence 44 rather than 45. This participant did not complete follow-up measures as they completed the shortened intervention
OST and injecting drug use behaviour
| Baseline whole cohort | Baseline for both measures cohort | Follow-up | |
|---|---|---|---|
| 25 (57) | 17 (57) | 20 (67) | |
| Years taking methadone | |||
| Median* [Q1, Q3] | 2 [0, 5] | 1 [0, 2] | 1 [0, 3] |
| Current dose (ml) | |||
| Median [Q1, Q3] | 70 [50, 100] | 78 [50, 98] | 60 [45, 90] |
| Years taking buprenorphine | |||
| Median (Min, Max) | 1 (1, 2) | 1 (1, 1) | 0 (0, 1) |
Cells are n and (%) except for rows with days which summarises median [25th, 75th centile] years of use. *0 years implies less than 1 year of duration
SURE and CARE scores at baseline and follow-up
| Baseline whole cohort | Baseline for both measures cohort | Follow-up | |
|---|---|---|---|
| Substance use | 12 [10, 14] | 12 [9,14] | 14 [10,16] |
| Self-care | 7 [6, 8] | 7 [5, 11] | 9 [6, 12] |
| Relationships | 4 [3,6] | 11 [8,12] | 10 [9,12] |
| Material resources | 11 [8.5,12] | 7 [85,8] | 7 [6,9] |
| Outlook | 7 [5.5,9.5] | 4 [3,6] | 5 [3,8] |
| Total | 41.5 [35,48] | 39.5 [34,48] | 46.5 [36,54] |
| 49.5 [43, 50] | 50 [43, 50] | 49 [46, 50] | |
Cells are median and [quartile 1, quartile 3]. Higher scores are better for SURE (for total min 21 to max 63) and CARE (min 10 to max 50)
Baseline and follow-up PHQ-9, GAD-7, PHQ-ADS and MAP-physical domain
| Baseline for whole cohort | Baseline for both measures cohort | Follow-up | |
|---|---|---|---|
| Mean (SD) | 15.5 (7.3) | 14.2 (7.3) | 13.6 (6.5 |
| Mean difference (95% CI) | − 0.6 (− 0.3 to 2.2) | ||
| Mean (SD) | 14.7 (6.1) | 14.3 (6.3) | 11.7 (6.9) |
| Mean difference (95% CI) | − 2.6 (− 5.4 to 0.2) | ||
| Mean (SD) | 30.2 (12.6) | 28.4 (11.9) | 25.3 (11.7) |
| Mean difference (95% CI) | − 3.1 (− 7.8 to 1.7) | ||
| Mean (SD) | 30.9 (13.4) | 31.0 (12.4) | 28.3 (12.7) |
| Mean difference (95% CI) | − 2.5 (− 6.6 to 1.5) | ||
Mean difference is follow-up-baseline. CI confidence interval. Higher score = more severe condition